Early Detection of CTEPH in Patients After APE

Launched by INSTITUTE OF HEALTH INFORMATION AND STATISTICS OF THE CZECH REPUBLIC · Mar 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a condition called Chronic Thromboembolic Pulmonary Hypertension (CTEPH), which can develop in some patients who have had an episode of acute pulmonary embolism (a blockage in the lung arteries). The main goal of the study is to find out the best ways to detect CTEPH early in patients after they have experienced a pulmonary embolism. This is important because early detection can help improve patients' health and make the healthcare process more effective and affordable.

To participate, you must be over 18 years old and have had a pulmonary embolism in the last 3 to 12 months while receiving blood-thinning medication. You might be eligible if you are experiencing ongoing shortness of breath or if you have certain risk factors, such as a serious heart condition or specific autoimmune diseases. Participants will undergo tests to check for CTEPH and will be monitored throughout the study. The trial is not yet recruiting, so it’s a good idea to stay informed about when it will begin if you think you might qualify.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age over 18 years
• • Signed consent to participate in the project and GDPR
• * Patients with an episode of acute pulmonary embolism in the last 3-12 months, with ongoing anticoagulation therapy:
• • 1. Patients with new-onset and ongoing or progressive dyspnea (min. NYHA II) after a pulmonary embolism episode or worsening of dyspnea after a pulmonary embolism episode compared to the status before the episode (at least 1 HYHA grade) or
• 2. Asymptomatic patients after a pulmonary embolism episode and at least one of the following risk factors:
• • ECHO evidence of severe PH at diagnosis of PE (PASP \>60 mmHg)
• • Antiphospholipid syndrome with triple positivity (presence of lupus anticoagulans + anti-beta-2-glycoprotein I (B2GPI) antibodies + anticardiolipin)
• • Infected permanent venous inlets and cardiac pacing/defibrillation intravascular systems
• • Presence of ventriculoatrial shunt for treatment of hydrocephalus
• • Nonspecific intestinal inflammation (ulcerative colitis, Crohn's disease)
• • History of splenectomy
• • Myeloproliferative disorders
• • Chronic osteomyelitis
• Exclusion Criteria:
• • Not agreeing to participate in the project
• • Contraindications to treatment